EPO invalidates Pacific Biosciences patent in Oxford Nanopore dispute

The European Patent Office (EPO) has revoked a patent held by a US biotechnology company, Pacific Biosciences, after its UK-based rival Oxford Nanopore Technologies challenged the validity of the patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Oxford Nanopore secures Fed Circ victory in PacBio DNA suit

13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.

Americas

Pacific Biosciences and Oxford Nanopore settle patent claims

9 May 2018 US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

EPO invalidates Pacific Biosciences patent in Oxford Nanopore dispute

More on this story

Editor's picks

Editor's picks

More features